PharmaTimes3d
Imfinzi receives NICE recommendation for lung cancer treatment
AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended by NICE for treating adults with ...
After Lung Cancer Approval, AstraZeneca's Imfinzi Goes Under FDA Priority Review For Bladder Cancer
AstraZeneca's Imfinzi gains FDA Priority Review for bladder cancer. Key trial data shows improved survival and progression ...
Priority FDA review given to AstraZeneca’s Imfinzi sBLA for MIBC
The US Food and Drug Administration (FDA) has granted priority review to AstraZeneca's supplemental biologics licence ...
IMFINZI® (durvalumab) granted Priority Review in the US for patients with muscle-invasive bladder cancer
AstraZeneca’s supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) has been accepted and granted Priority Review in the US for the treatment of patients with muscle-invasive ...
pulmonologyadvisor2d
Imfinzi Approved for Limited-Stage Small Cell Lung Cancer
The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has ...
Daily5d
AstraZeneca Imfinzi granted priority review by USFDA for muscle-invasive bladder cancer
Cambridge: AstraZeneca's supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab) has been accepted and ...
The Pharma Letter6d
Imfinzi recommended for rNSCLC
Imfinzi (durvalumab) has been recommended by the National Institute for Health and Care Excellence (NICE) for the treatment ...
Morningstar6d
IMFINZI® (durvalumab) granted Priority Review in the US for patients with muscle-invasive bladder cancer
AstraZeneca’s supplemental Biologics License Application (sBLA) for IMFINZI®(durvalumab) has been accepted and granted Priority Review in the US for the treatment of patients with muscle ...
FDA accepts AstraZeneca's sBLA for Imfinzi for bladder cancer
AstraZeneca (AZN) said the FDA has accepted its supplemental Biologics License Application for Imfinzi for Priority Review for the treatment of muscle-invasive bladder cancer.
AZN's Bladder Cancer sBLA for Imfinzi Gets FDA's Priority Tag
AstraZeneca AZN announced that the FDA has accepted and granted priority review to its supplemental biologics license application (sBLA) seeking expanded use of its blockbuster drug, Imfinzi ...